Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients

Simple item page
dc.citation.firstpage1205en_US
dc.citation.issueNumber7en_US
dc.citation.journalTitleCancer Researchen_US
dc.citation.lastpage1215en_US
dc.citation.volumeNumber75en_US
dc.contributor.authorOsman, Abdullah A.en_US
dc.contributor.authorNeskey, David M.en_US
dc.contributor.authorKatsonis, Panagiotisen_US
dc.contributor.authorPatel, Ameeta A.en_US
dc.contributor.authorWard, Alexandra M.en_US
dc.contributor.authorHsu, Teng-Kueien_US
dc.contributor.authorHicks, Stephanie C.en_US
dc.contributor.authorMcDonald, Thomas O.en_US
dc.contributor.authorOw, Thomas J.en_US
dc.contributor.authorAlves, Marcus Ortegaen_US
dc.contributor.authorPickering, Curtis R.en_US
dc.contributor.authorSkinner, Heath D.en_US
dc.contributor.authorZhao, Meien_US
dc.contributor.authorSturgis, Eric M.en_US
dc.contributor.authorKies, Merrill S.en_US
dc.contributor.authorEl-Naggar, Adelen_US
dc.contributor.authorPerrone, Federicaen_US
dc.contributor.authorLicitra, Lisaen_US
dc.contributor.authorBossi, Paoloen_US
dc.contributor.authorKimmel, Mareken_US
dc.contributor.authorFrederick, Mitchell J.en_US
dc.contributor.authorLichtarge, Olivieren_US
dc.contributor.authorMyers, Jeffrey N.en_US
dc.date.accessioned2017-05-15T17:23:57Zen_US
dc.date.available2017-05-15T17:23:57Zen_US
dc.date.issued2015en_US
dc.description.abstractTP53 is the most frequently altered gene in head and neck squamous cell carcinoma (HNSCC), with mutations occurring in over two thirds of cases; however, the predictive response of these mutations to cisplatin-based therapy remains elusive. In the current study, we evaluate the ability of the Evolutionary Action score of TP53-coding variants (EAp53) to predict the impact of TP53 mutations on response to chemotherapy. The EAp53 approach clearly identifies a subset of high-risk TP53 mutations associated with decreased sensitivity to cisplatin both in vitro and in vivo in preclinical models of HNSCC. Furthermore, EAp53 can predict response to treatment and, more importantly, a survival benefit for a subset of head and neck cancer patients treated with platinum-based therapy. Prospective evaluation of this novel scoring system should enable more precise treatment selection for patients with HNSCC.en_US
dc.identifier.citationOsman, Abdullah A., Neskey, David M., Katsonis, Panagiotis, et al.. "Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients." <i>Cancer Research,</i> 75, no. 7 (2015) AACR: 1205-1215. http://dx.doi.org/10.1158/0008-5472.CAN-14-2729.en_US
dc.identifier.doihttp://dx.doi.org/10.1158/0008-5472.CAN-14-2729en_US
dc.identifier.urihttps://hdl.handle.net/1911/94253en_US
dc.language.isoengen_US
dc.publisherAACRen_US
dc.rightsThis is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by AACR.en_US
dc.titleEvolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patientsen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpost-printen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Evolutionary-Action-Score.pdf
Size:
1.84 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Faculty Publications
Statistics Publications